Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
26 Apr 24
8-K
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
8-K
Termination of a Material Definitive Agreement
12 Feb 24
8-K
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
25 Jan 24
8-K
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
12 Jan 24
8-K
Regulation FD Disclosure
15 Nov 23
8-K
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Regulation FD Disclosure
13 Oct 23
8-K
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial
13 Oct 23
8-K
Regulation FD Disclosure
6 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
28 Feb 24
S-8
Registration of securities for employees
30 May 23
S-8
Registration of securities for employees
1 Mar 23
424B5
Prospectus supplement for primary offering
4 Aug 22
S-8
Registration of securities for employees
11 Mar 22
POS AM
Prospectus update (post-effective amendment)
7 Mar 22
POS AM
Prospectus update (post-effective amendment)
2 Mar 22
POSASR
Automatic shelf registration (post-effective amendment)
1 Mar 22
424B5
Prospectus supplement for primary offering
28 Oct 21
424B5
Prospectus supplement for primary offering
27 Oct 21
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
1 Apr 22
DEF 14A
Definitive proxy
1 Apr 22
DEFA14A
Additional proxy soliciting materials
1 Apr 21
DEF 14A
Definitive proxy
1 Apr 21
Other
EFFECT
Notice of effectiveness
26 Apr 22
EFFECT
Notice of effectiveness
19 Jun 20
CERT
Certification of approval for exchange listing
18 Jun 20
CORRESP
Correspondence with SEC
17 Jun 20
CORRESP
Correspondence with SEC
16 Jun 20
CORRESP
Correspondence with SEC
16 Jun 20
UPLOAD
Letter from SEC
16 Jun 20
CORRESP
Correspondence with SEC
4 Jun 20
CORRESP
Correspondence with SEC
29 May 20
UPLOAD
Letter from SEC
18 May 20
Ownership
4
Lloyd Mitchell Segal
1 Apr 24
4
Steve Forte
1 Apr 24
4
Michael Zinda
1 Apr 24
4
Maria Koehler
1 Apr 24
4
Steve Forte
27 Mar 24
4
Michael Zinda
27 Mar 24
4
Maria Koehler
27 Mar 24
4
Lloyd Mitchell Segal
27 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
144
Notice of proposed sale of securities
26 Mar 24